C 
China Resources Sanjiu Medical & Pharmaceutical Co 000999.SZ · CNY
Health Care · Shenzhen · 🇨🇳 China
25.69
-1.00%
Close of 9 Nov 2026, in CNY
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
At a glance
Figures in CNY, from our data supplier.
Revenue
CN¥31.60bn
FY2016FY2025
Net income
CN¥3.42bn
FY2016FY2025
Free cash flow
CN¥4.24bn
FY2016FY2025
Shareholders' equity
CN¥22.17bn
FY2016FY2025
Income statement
Fiscal years
| FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | CN¥31.60bn | CN¥27.62bn | CN¥24.74bn | CN¥18.08bn | CN¥15.54bn | CN¥13.64bn | CN¥14.79bn | CN¥13.43bn | CN¥11.12bn | CN¥8.98bn |
| Gross profit | CN¥17.04bn | CN¥14.18bn | CN¥13.06bn | CN¥9.73bn | CN¥8.98bn | CN¥8.49bn | CN¥9.89bn | CN¥9.26bn | CN¥7.22bn | CN¥5.60bn |
| Research and development | CN¥1.34bn | CN¥801.7m | CN¥767.6m | CN¥612.3m | CN¥30.6m | CN¥459.8m | CN¥455.8m | CN¥355.8m | CN¥297.3m | CN¥286.8m |
| Operating income | CN¥4.86bn | CN¥4.48bn | CN¥3.75bn | CN¥2.95bn | CN¥2.47bn | CN¥2.07bn | CN¥2.51bn | CN¥1.70bn | CN¥1.53bn | CN¥1.30bn |
| Net income | CN¥3.42bn | CN¥3.37bn | CN¥2.85bn | CN¥2.45bn | CN¥2.06bn | CN¥1.60bn | CN¥2.10bn | CN¥1.43bn | CN¥1.30bn | CN¥1.20bn |
| Diluted earnings per share | 2.04 | 2.00 | 1.71 | 1.44 | 1.25 | 0.95 | 1.26 | 0.85 | 0.79 | 0.71 |
Balance sheet
At each fiscal year end
| FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Total assets | CN¥58.80bn | CN¥40.08bn | CN¥40.15bn | CN¥27.12bn | CN¥24.54bn | CN¥22.15bn | CN¥21.40bn | CN¥18.03bn | CN¥16.20bn | CN¥13.55bn |
| Cash and short-term investments | CN¥9.56bn | CN¥6.69bn | CN¥8.23bn | CN¥3.15bn | CN¥4.28bn | CN¥4.02bn | CN¥3.09bn | CN¥2.48bn | CN¥1.71bn | CN¥1.31bn |
| Total liabilities | CN¥20.03bn | CN¥14.83bn | CN¥15.89bn | CN¥9.59bn | CN¥8.77bn | CN¥8.10bn | CN¥8.32bn | CN¥6.86bn | CN¥6.07bn | CN¥4.83bn |
| Debt | — | CN¥1.56bn | CN¥3.28bn | CN¥724.8m | CN¥657.3m | CN¥308.0m | CN¥349.0m | CN¥911.0m | CN¥964.0m | CN¥849.0m |
| Shareholders' equity | CN¥22.17bn | CN¥19.90bn | CN¥18.97bn | CN¥17.01bn | CN¥15.31bn | CN¥13.72bn | CN¥12.76bn | CN¥10.83bn | CN¥9.84bn | CN¥8.62bn |
| Shares outstanding | 1,673m | 1,683m | 1,669m | 1,701m | 1,642m | 1,677m | 1,662m | 1,684m | 1,654m | 1,685m |
Cash flow
Fiscal years
| FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash from operations | CN¥5.51bn | CN¥4.40bn | CN¥4.19bn | CN¥3.01bn | CN¥1.88bn | CN¥2.22bn | CN¥1.97bn | CN¥1.91bn | CN¥1.60bn | CN¥1.39bn |
| Capital spending | −CN¥1.27bn | −CN¥790.1m | −CN¥857.2m | −CN¥951.6m | −CN¥870.8m | −CN¥621.8m | −CN¥536.0m | −CN¥600.4m | −CN¥374.7m | −CN¥354.3m |
| Free cash flow | CN¥4.24bn | CN¥3.61bn | CN¥3.33bn | CN¥2.05bn | CN¥1.01bn | CN¥1.60bn | CN¥1.44bn | CN¥1.31bn | CN¥1.22bn | CN¥1.04bn |
| Dividends paid | −CN¥1.26bn | −CN¥2.83bn | −CN¥1.06bn | −CN¥841.9m | −CN¥496.1m | −CN¥420.9m | −CN¥381.8m | −CN¥491.3m | −CN¥181.6m | −CN¥170.0m |
Latest quarters
By quarter end
| Jun 2026 | Mar 2026 | Dec 2025 | Sept 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sept 2024 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | CN¥6.88bn | CN¥8.13bn | CN¥9.62bn | CN¥7.18bn | CN¥7.96bn | CN¥6.85bn | CN¥7.88bn | CN¥5.63bn |
| Gross profit | CN¥3.84bn | CN¥4.69bn | CN¥5.27bn | CN¥3.89bn | CN¥4.23bn | CN¥3.65bn | CN¥3.78bn | CN¥2.87bn |
| Operating income | CN¥1.15bn | CN¥1.59bn | CN¥1.35bn | CN¥804.7m | CN¥964.9m | CN¥1.66bn | CN¥588.2m | CN¥749.0m |
| Net income | CN¥594.9m | CN¥1.08bn | CN¥1.07bn | CN¥537.6m | CN¥545.2m | CN¥1.27bn | CN¥408.1m | CN¥561.5m |
| Diluted earnings per share | 0.36 | 0.64 | 0.64 | 0.32 | 0.33 | 0.76 | 0.24 | 0.33 |
| Cash from operations | — | — | CN¥2.60bn | CN¥126.0m | CN¥1.88bn | CN¥979.0m | CN¥1.20bn | CN¥841.0m |
| Capital spending | −CN¥282.0m | −CN¥236.0m | −CN¥545.0m | −CN¥302.0m | −CN¥268.0m | −CN¥155.0m | −CN¥267.0m | −CN¥198.0m |
| Free cash flow | — | — | CN¥2.06bn | −CN¥176.0m | CN¥1.61bn | CN¥824.0m | CN¥930.0m | CN¥643.0m |
| Total assets | CN¥55.84bn | CN¥58.14bn | CN¥58.80bn | CN¥56.56bn | CN¥57.26bn | CN¥57.85bn | CN¥40.08bn | CN¥40.77bn |
| Cash and short-term investments | — | — | CN¥9.56bn | CN¥8.58bn | CN¥9.67bn | CN¥10.55bn | CN¥6.69bn | CN¥8.85bn |
| Debt | CN¥2.85bn | CN¥3.48bn | CN¥6.29bn | CN¥2.95bn | CN¥5.04bn | CN¥3.51bn | CN¥1.03bn | CN¥2.20bn |
| Shareholders' equity | CN¥22.83bn | CN¥23.25bn | CN¥22.17bn | CN¥21.12bn | CN¥21.34bn | CN¥21.18bn | CN¥19.90bn | CN¥20.53bn |
Financial ratios
Data as of 18 Sept 2026
| FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | |
|---|---|---|---|---|---|---|
| Gross margin | 53.9% | 51.4% | 52.8% | 53.8% | 57.8% | 62.3% |
| Operating margin | 15.4% | 16.2% | 15.2% | 16.3% | 15.9% | 15.2% |
| Net margin | 10.8% | 12.2% | 11.5% | 13.5% | 13.2% | 11.7% |
| Return on equity | 15.4% | 16.9% | 15.0% | 14.4% | 13.4% | 11.6% |
| Return on assets | 5.8% | 8.4% | 7.1% | 9.0% | 8.4% | 7.2% |
| Free cash flow yield | 13.8% | 11.0% | 10.5% | 7.4% | 4.8% | 5.6% |
| Revenue growth | 14.4% | 11.6% | 36.8% | 16.3% | 14.0% | -7.8% |
| Earnings growth | 1.6% | 18.1% | 16.5% | 19.2% | 28.6% | -23.9% |
| Current ratio | 1.83x | 1.61x | 1.74x | 1.38x | 1.60x | 1.50x |
| Debt to equity | 0.28x | 0.05x | 0.14x | 0.01x | 0.01x | 0.00x |
| Equity ratio | 37.7% | 49.7% | 47.2% | 62.7% | 62.4% | 61.9% |
| Interest coverage | 39.66x | 53.23x | 44.07x | 129.60x | 149.54x | 300.61x |
| R&D as a share of sales | 4.2% | 2.9% | 3.1% | 3.4% | 0.2% | 3.4% |
| Buybacks as a share of market value | 0.6% | -0.9% | 1.9% | -3.6% | 2.1% | -0.9% |
Growth per year
Compound annual rate
| 3 years | 5 years | 10 years | |
|---|---|---|---|
| Revenue | 20.5% | 18.3% | 14.9% |
| Operating income | 18.1% | 18.6% | 12.9% |
| Net income | 11.8% | 16.5% | 10.6% |
Average margins
Over each period
| 1 year | 3 years | 5 years | 10 years | |
|---|---|---|---|---|
| Gross margin | 52.7% | 52.9% | 54.5% | 57.8% |
| Operating margin | 15.8% | 15.7% | 15.7% | 15.5% |
| Net margin | 11.5% | 11.8% | 12.0% | 12.3% |
Valuation history
At each fiscal year end
| FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Price to earnings | 13.9 | 17.1 | 17.2 | 19.2 | 16.2 | 15.5 | 14.8 | 17.3 | 20.4 | 20.6 |
| Price to sales | 1.5 | 2.1 | 2.0 | 2.6 | 2.1 | 1.8 | 2.1 | 1.8 | 2.4 | 2.7 |
Dividends and splits
Per share, in the currency the company pays
Paid for 17 years. Last went ex-dividend on 29 May 2026.
| FY2026 | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | |
|---|---|---|---|---|---|---|---|---|
| Paid in the year | 0.59 | 0.696 | 1.923 | 0.592 | 0.505 | 0.296 | 0.254 | 0.231 |
- 13-for-10 split · 6 Jun 2025
- 13-for-10 split · 14 Jun 2024
- 1-to-1 reverse split · 5 Dec 2008
- 13-for-10 split · 11 Jun 2003
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.